Norwood, MA, March 22, 2010 - Molecular Biometrics, Inc., a metabolomics company developing novel clinical diagnostic tools for applications in personalized medicine, today announced that the company has received the Frost & Sullivan 2010 North American Technology Innovation of the Year Award in the field of Applied Metabolomic Analytics. ViaMetrics-E, the first product based on the Company’s proprietary technology platform, is a rapid, non-invasive procedure designed to enhance in vitro fertilization (IVF) outcomes for couples experiencing infertility. ViaMetrics-E is designed to aid in the identification of embryos having the greatest reproductive potential, thus improving IVF pregnancy rates, and ultimately reducing the need to transfer multiple embryos during an IVF cycle and the complications and healthcare costs that accompany multiple births.

"This prestigious award further validates our technology and the company’s leadership in developing novel, innovative and cutting-edge technology to satisfy unmet clinical needs in reproductive medicine and potentially in neurodegenerative diseases such as Parkinson’s disease,” said James T. Posillico, PhD, President and Chief Executive Officer, Molecular Biometrics. “We are honored to be recognized for our innovations by Frost & Sullivan.”

According to Frost & Sullivan, the biospectroscopy-based metabolomic technologies developed by Molecular Biometrics “exemplify a pioneering solution to address the gap in translating latent physiological conditions to accurate diagnosis thereby offering the possibility of making biological assessment non-invasive and accurate apart from diversification of the platform into several applications.” For the Technology Innovation Award, uniqueness of the technology and its impact on new products/applications were the criteria used to benchmark Molecular Biometrics’ performance against other innovators in the metabolomics field.

ViaMetrics-E is available commercially in Australia, Japan, the U.K., Ireland and Greece, and the company expects to launch the product in other countries in Europe and Asia in 2010. Molecular Biometrics is also working to complete the necessary regulatory requirements for clearance from the U.S. Food and Drug Administration.

About ViaMetrics-E™

ViaMetrics-E is a rapid, non-invasive procedure for in vitro fertilization (IVF) designed to aid in the assessment of viable embryos with the greatest reproductive potential. As embryos develop they undergo specific metabolic changes and produce biological signals or “biomarkers” that are absorbed into the culture media that nourishes these cells. Using a highly sensitive method of biomarker identification (metabolomics), ViaMetrics-E then measures these signals in the spent culture media, creating a ‘fingerprint’ or biomarker profile to help determine embryo viability. Analysis can be performed in an infertility laboratory in just minutes. ViaMetrics-E provides objective assessment of viability without compromising the embryo, helping guide treatment options for patients undergoing IVF. ViaMetrics-E is not currently cleared for use in the U.S. by the Food and Drug Administration.

About Molecular Biometrics®

Molecular Biometrics, Inc. is applying novel metabolomic technologies to develop accurate, non-invasive clinical tools for use in personalized medicine to evaluate normal biologic function in health and in disease, and for drug discovery and development. The company’s proprietary technology is being applied in reproductive health, IVF and neurodegenerative disease (e.g., Parkinson’s disease). Molecular Biometrics is headquartered in Norwood, MA, with research and development facilities in New Haven, CT. For more information, please visit www.molecularbiometrics.com.

Note: This press release contains forward-looking statements about the objectives, plans and future prospects of Molecular Biometrics®, Inc. These statements are based on the company's current expectations and are subject to a number of uncertainties and risks, and actual outcomes and results may differ materially. Accordingly, forward-looking statements should not be regarded as a representation or warranty by Molecular Biometrics or any third party that the company’s objectives and plans will be achieved in any specific time frame, if at all.